Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes

NCT03444142 on ClinicalTrials.gov · last registry update 2020-03-26

A small phase 4 — 30 participants, against a typical 75. Its estimated completion date, 30 November 2021, has passed with no update to the record. Primary outcome, as filed: Heart rate: nighttime, daytime and 24-h. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P4
Drug: dulaglutide
Trulicity
Sponsor: University of Guadalajara
Sponsor type: Other
Enrollment: 30
Started: 2017-11-17
Primary completion: 2021-11-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Heart rate: nighttime, daytime and 24-h

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.